Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 1
2015 2
2017 2
2018 2
2019 2
2020 2
2021 2
2022 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

15 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean hengyi xu[Author] (181 results)?
Mitapivat versus Placebo for Pyruvate Kinase Deficiency.
Al-Samkari H, Galactéros F, Glenthøj A, Rothman JA, Andres O, Grace RF, Morado-Arias M, Layton DM, Onodera K, Verhovsek M, Barcellini W, Chonat S, Judge MP, Zagadailov E, Xu R, Hawkins P, Beynon V, Gheuens S, van Beers EJ; ACTIVATE Investigators. Al-Samkari H, et al. Among authors: xu r. N Engl J Med. 2022 Apr 14;386(15):1432-1442. doi: 10.1056/NEJMoa2116634. N Engl J Med. 2022. PMID: 35417638 Clinical Trial.
Mitapivat in adult patients with pyruvate kinase deficiency receiving regular transfusions (ACTIVATE-T): a multicentre, open-label, single-arm, phase 3 trial.
Glenthøj A, van Beers EJ, Al-Samkari H, Viprakasit V, Kuo KHM, Galactéros F, Chonat S, Porter J, Zagadailov E, Xu R, Oluyadi A, Hawkins P, Gheuens S, Beynon V, Barcellini W; ACTIVATE-T investigators. Glenthøj A, et al. Among authors: xu r. Lancet Haematol. 2022 Oct;9(10):e724-e732. doi: 10.1016/S2352-3026(22)00214-9. Epub 2022 Aug 18. Lancet Haematol. 2022. PMID: 35988546 Clinical Trial.
A novel differentiation response with combination IDH inhibitor and intensive induction therapy for AML.
Mason EF, Pozdnyakova O, Roshal M, Fathi AT, Stein EM, Ferrell PB, Shaver AC, Frattini M, Wang H, Hua L, Mu J, Choe S, Xu R, Almon C, Cooper M, Stone RM, Hasserjian RP, Savona MR. Mason EF, et al. Among authors: xu r. Blood Adv. 2021 Apr 27;5(8):2279-2283. doi: 10.1182/bloodadvances.2020003685. Blood Adv. 2021. PMID: 33904894 Free PMC article. No abstract available.
Framework for assessment and phytoremediation of asbestos-contaminated sites.
Gonneau C, Miller K, Mohanty SK, Xu R, Hwang WT, Willenbring JK, Casper BB. Gonneau C, et al. Among authors: xu r. Environ Sci Pollut Res Int. 2017 Nov;24(33):25912-25922. doi: 10.1007/s11356-017-0177-x. Epub 2017 Sep 22. Environ Sci Pollut Res Int. 2017. PMID: 28940054 Free PMC article.
15 results